LSP Dementia Fund
The LSP Dementia Fund is a venture capital fund managed by EQT Life Sciences (formerly LSP) dedicated to investing in innovative companies developing products and technologies targeting neurodegenerative diseases and dementia. Launched in 2020, the fund closed at approximately EUR 273 million, with investments typically ranging between EUR 5 million and EUR 25 million.
40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (80% of deals). Average disclosed round size is $94.0M (across 3 rounds with reported amounts).
Portfolio
5
Fund Size
$297M
Top Stage
Series A
Last 12 Mo
0
Team
Arno de Wilde
Managing Director
Cillian King
Partner
Felice Verduyn - Van Weegen
Partner
Juliette Lee
Vice President
Philip Scheltens
Head of fund
Portfolio Breakdown
Stage Distribution
Sector Distribution
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Muna Therapeutics | Series A | $73M | Jul 2021 |
| NNewAmsterdam Pharma | Series A | — | Jan 2021 |
 Nobi | Unknown | $13M | — |
 New Amsterdam Pharma | Series A | $196M | — |
| NNewAmsterdam | Series A | — | — |
Top Co-Investors
Last updated: 7 October 2026